Health and Healthcare
Short Sellers, No Direction in Biotech (AMGN, BIIB, CELG, GENZ, GILD)
Published:
It seems that short sellers have no real direction in the major NASDAQ biotech stocks from mid-November to late-November. Generally you see a pattern. This month the only pattern seems to be one of no conviction either way. Here are the short seller reports in the short interest:
Stock (Ticker) NOV. 28 NOV. 14 CHANGE
Amgen Inc. (AMGN) 23,033,081 24,169,278 -4.70%
Celgene Corporation (CELG) 8,298,820 8,040,642 +3.21%
Biogen Idec Inc. (BIIB) 8,027,848 7,938,637 +1.12%
Genzyme Corporation (GENZ) 6,569,181 6,797,501 -3.36%
Gilead Sciences (GILD) 29,055,791 30,213,915 -3.83%
Jon C. Ogg
December 10, 2008
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
